Why the Rhythm Biosciences (ASX:RHY) share price is flying higher today

Capital raisings can fund new product developments and help fuel company growth plans

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is charging higher in afternoon trade, up 7% to $1.21 per share.

Below we take a look at what's driving investor interest in the ASX medical diagnostics technology company.

Group of medical professionals high five

Image source: Getty Images

What did Rhythm announce?

The Rhythm Biosciences share price is gaining after the company reported it had successfully completed its non-renounceable pro-rata rights issue to raise $4.3 million, before costs.

While Rhythm set out to raise $4.3 million, it said actual subscriptions – including "entitlements, additional shares applied for, and letter of commitments" – totalled $12.05 million.

With actual subscriptions some 280% more than Rhythm was seeking, it said its share registry will return funds to unsuccessful applicants "as soon as practicable".

As interest ran stronger than anticipated, the company said it will now offer a small "heavily scaled back placement". This will select sophisticated and other exempt investors who had provided commitment letters for the previous offer.

Up to 1.5 million shares will be issued at a price of 85 cents per share to raise $1.28 million before costs. Rhythm said participants will also be offered 2 varieties of attaching, unlisted options.

John Hancock, who cornerstoned the placement, said: "The innovative ColoSTAT product, developed from research by the CSIRO and Rhythm, has the potential to be a global game-changer in the early mass-market screening for colorectal cancer."

Commenting on the offer, Rhythm's CEO, Glenn Gilbert said:

I'm pleased that the offer was strongly supported by existing shareholders, alongside the board and myself, further demonstrating our alignment. Coupled with an R&D tax incentive refund, expected shortly, the company is well funded to execute on our development and commercialisation plans outlined in our FY22 strategic plan.

Rhythm Biosciences share price snapshot

The Rhythm Biosciences share price has gained an eye-popping 991% over the past 12 months. Over that same time, the All Ordinaries Index (ASX: XAO) is up 27%.

Over the past month, Rhythm's shares are up 24%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist looking stressed out while working on a computer in a lab.
Broker Notes

What's Bell Potter's updated view on CSL shares?

Will the new tariffs impact CSL according to Bell Potter?

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Are Cogsgate shares a buy, hold or sell after rocketing 12% higher yesterday?

This broker thinks there could be more growth to come.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

Is this battered ASX biotech stock ready to rocket higher?

Brokers are upbeat and see upside of up to 125%!

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Why are CSL shares struggling to regain momentum?

Analysts have widely considered the shares to be oversold for some time now.

Read more »

Happy man working on his laptop.
Healthcare Shares

This ASX healthcare stock is up 70% in a year and climbing again today

Another strong quarter keeps the Cogstate stock in focus.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX healthcare stock could more than double according to Canaccord Genuity

It's shaping up as a big year for this drug developer.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off

Neuren shares jump after DAYBUE STIX expands across the US.

Read more »